Lucid Diagnostics (LUCD) Gross Margin (2021 - 2026)
Lucid Diagnostics (LUCD) posted Gross Margin of 25.0% for Q1 2026, down 3.45% on a QoQ basis from 24.17% in Q4 2025, and up 6232.0% year-over-year from 0.39% in Q1 2025.
Lucid Diagnostics (LUCD) Gross Margin (2021 - 2026) Analysis & Trends
Lucid Diagnostics' Gross Margin history runs 6 years deep, the most recent figure standing at 25.0% for Q1 2026.
- Quarterly Gross Margin rose 6232.0% year-over-year to 25.0% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 29.49% (up 3811.0% YoY) and the FY2025 annual result came in at 41.91%, up 2143.0% from the prior year.
- Gross Margin was 25.0% for Q1 2026 at Lucid Diagnostics, down from 24.17% in the prior quarter.
- Across five years, Gross Margin topped out at 100.0% in Q3 2022 and bottomed at 874.21% in Q2 2023.
- A 5-year average of 98.67% and a median of 54.53% in 2024 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2023 — Gross Margin tumbled 20868 bps — and 2024, when it soared 80884 bps.
- Lucid Diagnostics' Gross Margin stood at 100.0% in 2022, then plunged by 140 bps to 40.1% in 2023, then tumbled by 98 bps to 79.2% in 2024, then surged by 69 bps to 24.17% in 2025, then retreated by 3 bps to 25.0% in 2026.
- Business Quant data shows LUCD's Gross Margin at 25.0% in Q1 2026, 24.17% in Q4 2025, and 40.13% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 56.20% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 63.29% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 65.35% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 69.46% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 78.01% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 62.95% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 45.22% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 38.53% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Lucid Diagnostics | 133.09 Mn | 105.22 Mn | -325,000.00 | -25.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25.00% |
| Dec 31, 2025 | -24.17% |
| Sep 30, 2025 | -40.13% |
| Jun 30, 2025 | -30.25% |
| Mar 31, 2025 | -87.32% |
| Dec 31, 2024 | -79.20% |
| Sep 30, 2024 | -43.69% |
| Jun 30, 2024 | -65.37% |
| Mar 31, 2024 | -65.43% |
| Dec 31, 2023 | -40.10% |
| Sep 30, 2023 | -108.68% |
| Jun 30, 2023 | -874.21% |
| Mar 31, 2023 | -200.00% |
| Dec 31, 2022 | 100.00% |
| Sep 30, 2022 | 100.00% |
| Mar 31, 2022 | -95.24% |
| Dec 31, 2021 | 100.00% |
| Sep 30, 2021 | 100.00% |